Cargando…
PDX1 DNA Methylation Distinguishes Two Subtypes of Pancreatic Neuroendocrine Neoplasms with a Different Prognosis
DNA methylation is a crucial epigenetic mechanism for gene expression regulation and cell differentiation. Furthermore, it was found to play a major role in multiple pathological processes, including cancer. In pancreatic neuroendocrine neoplasms (PNENs), epigenetic deregulation is also considered t...
Autores principales: | Boons, Gitta, Vandamme, Timon, Ibrahim, Joe, Roeyen, Geert, Driessen, Ann, Peeters, Dieter, Lawrence, Ben, Print, Cristin, Peeters, Marc, Van Camp, Guy, Op de Beeck, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352978/ https://www.ncbi.nlm.nih.gov/pubmed/32512761 http://dx.doi.org/10.3390/cancers12061461 |
Ejemplares similares
-
Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations
por: Boons, Gitta, et al.
Publicado: (2018) -
Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
por: Boons, Gitta, et al.
Publicado: (2022) -
The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses
por: Ungefroren, Hendrik, et al.
Publicado: (2022) -
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016) -
The Gasdermin E Gene Has Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types
por: Ibrahim, Joe, et al.
Publicado: (2019)